COG112, ApoE Mimetic Peptide

COG112 ApoE Mimetic Peptide | Anti-Inflammatory & Neuroprotective Research Peptide

Product Overview:

COG112 is a synthetic Apolipoprotein E (ApoE) mimetic peptide designed by conjugating the receptor-binding domain of ApoE (COG133) with the cell-penetrating peptide (CPP) antennapedia (Antp). This modification significantly enhances the peptide’s anti-inflammatory properties and neuroprotective effects compared to COG133 alone.

Sequence:

acetyl-YRQIKIWFQNRRMKWKKCLRVRLASHLRKLRKRLL-amide

Molecular Formula:

C₂₀₂H₃₄₇N₇₁O₃₈S₂

Molecular Weight:

4460.51 g/mol

Key Features and Uses:

●  ApoE mimetic peptide COG112 is extensively studied for its ability to modulate inflammatory responses, primarily by inhibiting the NF-κB signaling pathway.

●Exhibits potent anti-inflammatory properties useful for research into neurodegenerative diseases and inflammatory bowel disease.

●     Compared to the original ApoE peptide COG133, COG112 demonstrates enhanced cell penetration and therapeutic efficacy due to the CPP antennapedia conjugation.

●   Recent research highlights the role of COG112 in cancer biology by inhibiting the SET-Rac1 interaction, resulting in decreased cancer cell migration and invasion.

●  COG112 peptide is widely used in anti-inflammatory uses and ApoE peptide research studies to explore novel therapeutic applications.

Research Insights:

●    COG112 vs COG133 ApoE peptide: The addition of the CPP domain in COG112 dramatically improves cellular uptake and anti-inflammatory activity compared to COG133 alone, making it a superior candidate for experimental therapies targeting inflammation and neuroprotection.

●Potential applications include modulation of inflammatory bowel disease, neurodegenerative disorders such as Alzheimer’s disease, and oncology research focused on tumor invasion and metastasis.

Product Applications:

Ideal for scientists and researchers investigating:

●      Inflammatory signaling pathways (e.g., NF-κB inhibition)

●      Neuroprotection mechanisms

●      Cancer cell migration and invasion pathways

●      Novel peptide therapeutics development

CAS #: NA